BioVie Inc. is a clinical-stage company. The Company is developing drug therapies to treat chronic debilitating conditions, including liver disease and neurological and neuro-degenerative disorders and certain cancers. In liver disease, the Company's orphan drug candidate BIV201 (continuous infusion terlipressin) is developed as a future treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by nonalcoholic steatohepatitis (NASH), hepatitis, and alcoholism. The Company is also engaged in developing NE3107, an extracellular single-regulated kinase (ERK) inhibitor that selectively reduces neuroinflammation and insulin resistance. NE3107 is an orally administered small molecule to inhibit inflammation-driven insulin resistance and pathological inflammatory cascades.
Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.